Multiple sclerosis in Ireland : costs, health-related quality of life and cost effectiveness of disease-modifying therapies
Citation:
Emer Fogarty, 'Multiple sclerosis in Ireland : costs, health-related quality of life and cost effectiveness of disease-modifying therapies', [thesis], Trinity College (Dublin, Ireland). School of Medicine. Discipline of Pharmacology & Therapeutics, 2014, pp 365Download Item:
Abstract:
This study aimed to evaluate the economic and health-related quality of life (HRQoL) burden of multiple sclerosis (MS) in Ireland, and to develop a framework for assessing the cost effectiveness of disease-modifying therapies (DMT). In achieving these aims, a cost-of-illness (Col) study estimated the direct and indirect costs of MS from the Irish healthcare payer and societal perspectives; the relationship between MS disability and HRQoL was explored; and the relative efficacy of DMT was assessed by network meta-analysis (NMA). Each of these elements was integrated into a decision-analytic model which was developed to estimate the cost effectiveness of DMT in Ireland.
Author: Fogarty, Emer
Advisor:
Barry, MichaelQualification name:
Doctor of Philosophy (Ph.D.)Publisher:
Trinity College (Dublin, Ireland). School of Medicine. Discipline of Pharmacology & TherapeuticsNote:
TARA (Trinity’s Access to Research Archive) has a robust takedown policy. Please contact us if you have any concerns: rssadmin@tcd.ieType of material:
thesisCollections
Availability:
Full text availableMetadata
Show full item recordLicences: